Table 1.
Baseline characteristics of patients with NSCLC who received SNK01 (NK cells) in combination with either gemcitabine/carboplatin or gemcitabine/carboplatin/cetuximab
| Variables | Total number of patients (n=12) |
| Age | 60.9±5.5 |
| Sex, male | 4 (33.3) |
| Pathology, adenocarcinoma | 12 (100) |
| ECOG PS, 1 | 12 (100) |
| Previous treatment line | |
| 1 | 3 (25.0) |
| 2 | 7 (58.3) |
| ≥3 | 2 (16.7) |
| Osimertinib resistance | 7 (58.3) |
| EGFR | |
| Wild type | 0 (0) |
| Mutation | 12 (100) |
| ALK | |
| Wild type | 11 (91.7) |
| Mutation | 0 (0) |
| Unknown | 1 (8.3) |
| PD-L1 status | |
| <1% | 2 (16.7) |
| 1%–49% | 2 (16.7) |
| ≥50% | 1 (8.3) |
| Unknown | 7 (58.3) |
| Baseline NK cell activity (pg/mL) | 667.0 (145.0–902.5) |
Data are presented as number (percentage), mean±SD, or median (IQR).
ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; NK, natural killer; NSCLC, non-small cell lung cancer.